Literature DB >> 12034166

Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL.

Alison Coletta1, Simon Thackray, Nikolay Nikitin, John G F Cleland.   

Abstract

This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the American College of Cardiology 51st Annual Scientific Session held in Atlanta on 17-20 March 2002. Reports of the following clinical studies are included: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL.

Entities:  

Mesh：

Year:  2002        PMID： 12034166     DOI： 10.1016/s1388-9842(02)00040-5

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


  6 in total

Review 1.  Autonomic changes in patients with heart failure and in post-myocardial infarction patients.

Authors:  M P Frenneaux
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

2.  Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure.

Authors:  S J Leslie; J C S Spratt; S P McKee; F E Strachan; D E Newby; D B Northridge; M A Denvir; D J Webb
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

Review 3.  Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.

Authors:  Giuseppe Boriani; Mauro Biffi; Igor Diemberger; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

5.  Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide.

Authors:  Stephen J Leslie; Mamun Q Rahman; Martin A Denvir; David E Newby; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

6.  Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling.

Authors:  Lorenz H Lehmann; Julia S Rostosky; Sebastian J Buss; Michael M Kreusser; Jutta Krebs; Walter Mier; Frank Enseleit; Katharina Spiger; Stefan E Hardt; Thomas Wieland; Markus Haass; Thomas F Lüscher; Michael D Schneider; Rosanna Parlato; Hermann-Josef Gröne; Uwe Haberkorn; Masashi Yanagisawa; Hugo A Katus; Johannes Backs
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.